A PHASE II, MULTICENTER, RANDOMIZED, ACTIVE TREATMENT?CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Save

Date Added
April 1st, 2016
PRO Number
Pro00043506
Researcher
W. lloyd Clark
Keywords
Vision/ Eye
Summary

Study GX28228 is a Phase II, multicenter, randomized, active treatment (monthly ITV injection)?controlled study to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the Implant using three ranibizumab formulation arms (10 mg/mL, 40 mg/mL, and 100 mg/mL) compared with the control arm (0.5-mg monthly ITV injections of 10-mg/mL formulation) in patients with subfoveal neovascular (wet) AMD. The study will also evaluate the safety of the RPDS combination product.

Institution
Palmetto
Recruitment Contact
Tiffany Swinford
803-404-5037
tswinford@palmettoretina.com

Change_preferences

-- OR --

Create_login